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Consumption ofmultiplemicronutrient supplements (MMS) during pregnancy offers additional benefits compared
with iron-folic acid (IFA) supplementation, but the tablets are more expensive. We estimated the effects, costs, and
cost-effectiveness of hypothetically replacing IFA supplements with MMS for 1 year in Bangladesh and Burkina
Faso. Using baseline demographic characteristics from LiST and effect sizes from ameta-analysis, we estimated the
marginal effects of replacing IFA withMMS onmortality, adverse birth outcomes, and disability-adjusted life years
(DALYs) averted. We calculated the marginal tablet costs of completely replacing MMS with IFA (assuming 180
tablets per covered pregnancy). Replacing IFAwithMMS could avert over 15,000 deaths and 30,000 cases of preterm
birth annually in Bangladesh and over 5000 deaths and 5000 cases of preterm birth in Burkina Faso, assuming 100%
coverage and adherence. We estimated the cost per death averted to be US$175–185 in Bangladesh and $112–125
in Burkina Faso. Cost per DALY averted ranged from $3 to $15, depending on the country and consideration of
subgroup effects. Our estimates suggest that this policy change would cost-effectively save lives and reduce life-
long disabilities. Improvements in program delivery and supplement adherence would be expected to improve the
cost-effectiveness of replacing IFA with MMS.
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Introduction
Adequate nutrition during pregnancy has long been
recognized as essential for the health of mothers
and their infants.1 For decades, WHO has recom-
mended provision of iron-folic acid (IFA) supple-
ments as part of routine antenatal care2 and, as
a result, most countries include IFA consumption
during pregnancy in their national nutrition plan.
The WHO guideline for IFA provision is based
on expected effects of IFA on women’s health and
birth outcomes, especially low birth weight (LBW),
preterm birth, maternal anemia at term, and mater-
nal iron deficiency at term.3
There is ample evidence that deficiencies in other
micronutrients, such as zinc, iodine, and vitamin
A, affect fetal growth and development, and that
these deficiencies are prevalent in low- and middle-
income countries.4 In randomized, controlled trials,
multiple micronutrient supplements (MMS) during
pregnancy reduced the risk of small for gestational
age (SGA) and LBW, in comparison with standard
IFA supplementation.5 Effects of MMS compared
with IFAon other key outcomes, such as infantmor-
tality, have been reported for specific subgroups.6
However, WHO does not currently recommend
MMS for pregnant women to improvematernal and
perinatal outcomes,1 citing gaps in evidence as well
as potential increased risk of pregnancy compli-
cations owing to increased incidence of large-for-
gestational age (LGA).
The WHO recommendation related to MMS
does note that “policymakers in populations with
a high prevalence of nutritional deficiencies might
doi: 10.1111/nyas.14132
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consider the benefits of multiple micronutrient
supplements on maternal health to outweigh the
disadvantages, and may choose to give multiple
micronutrient supplements that include iron and
folic acid.”1 To make this decision, policymakers
must consider not only the health benefits of such
a policy change, but also the costs. Moreover, they
must weigh these costs against those of alternative
opportunities to invest in population health, includ-
ing improving the performance of current IFA pro-
grams and promoting other societal priorities.
To help guide these decisions, the objective of this
analysis was to estimate the effectiveness and cost-
effectiveness of hypothetically replacing IFA supple-
ments with MMS for 1 year in the context of an
ongoing program to deliver supplements to preg-
nant women in Bangladesh and Burkina Faso. We
first estimated the marginal effects of replacing IFA
withMMSonmortality and selected birth outcomes
in each context, and then summarized these effects
as measured by the resulting disability-adjusted life
years (DALYs) averted. For each country, we then
estimated the marginal costs of instantly and com-
pletely replacing MMS with IFA (considering costs
of tablets only, but not other program transition
costs, some of which occur over several years) and
calculated cost per case of mortality, birth outcome,
and DALY averted. We estimated all outcomes for
a single year (2018) for a hypothetical scenario of
100% coverage and for current levels of IFA cov-
erage (nationally ∼50% for Bangladesh and ∼10%
for Burkina Faso), but assuming perfect program
management and perfect adherence in both scenar-
ios (i.e., no tablet waste and consumption of 180
tablets for each covered pregnancy; these assump-
tions will be examined in more detail in subsequent
work).
Methods
Scenarios modeled
We calculated the additional costs and benefits of
replacing all IFA tablets withMMS. For the primary
analysis, we used effect sizes from all trials included
in a recent meta-analysis,6 using both the overall
effects of MMS compared with IFA and incorpo-
rating effect modification, where statistically sig-
nificant. In the primary hypothetical scenario, we
assumed 100% coverage and adherence; that is, the
costs and benefits were calculated on the basis of the
assumption that all pregnant women received and
consumed 180 tablets per pregnancy.
To examine the effect of assumptions about
supplement coverage on effectiveness and cost-
effectiveness estimates, we also applied coverage
estimates equivalent to current IFA coverage in
Bangladesh (∼50% nationally, 60.7% urban and
47.4% rural7) and in Burkina Fasoa (10.2% nation-
ally, 16.0% urban and 8.4% rural8); for these sce-
narios, wemaintained the assumption of 180 tablets
consumed per “covered” pregnancy and no tablet
waste.
Finally, we also examined variation in the results
when calculated using the marginal effects of MMS
reported for a subset of trials that used equal doses
of iron in the MMS and IFA tablets.6
Model structure
All calculations were performed in MS Excel and
show single-year values for 2018. Calculations were
conducted separately for four strata in each coun-
try: Urban, Male Child; Urban, Female Child;
Rural, Male Child; Rural, Female Child. The strata
were selected on the basis of expected differences
in (1) supplementation program implementation
costs, (2) program coverage, and (3) adult economic
returns (urban versus rural location), (4) future
labor force participation rates of children, and (5)
differing marginal impact of MMS compared with
IFA (male versus female children). Differences in
program coverage by urban versus rural strata and
effectmodification by child sex are addressed in this
report; remaining factors will be explored in subse-
quent work. The results for expected benefits (cases
aAnalysis of Demographic and Health Surveys (DHS)
microdata allowed for a more refined assessment of IFA
consumption in Burkina Faso: nationally 51.4% (59.2% in
urban areas, 48.91% in rural areas) of pregnant women
reported consuming at least 90 IFA tablets, and 10.2%
(16.0% urban and 8.4% rural) reported consuming at
least 180 IFA tablets during their most recent preg-
nancy. Similar data are not available for IFA consump-
tion in Bangladesh, for which the coverage estimates
applied here are the proportion of women who took
any IFA during their previous or current pregnancy
(WFP/UNICEF/IHPN 2009). The results presented here
assume that all covered pregnant women consume exactly
180 tablets, which is consistent with the coverage calcu-
lated for Burkina Faso but likely an overestimate of the
benefits in Bangladesh.
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of mortality and birth outcomes averted, years of
life lost (YLL) averted, and DALYs saved) and costs
were then summed to produce national-level esti-
mates of benefits, costs, and cost-effectiveness.
Data sources and assumptions: mortality and
birth outcomes
For both countries, we extracted baseline demo-
graphic information regarding the size, age
structure, and urban/rural distribution of the
populations from the Lives Saved Tool (LiST),
using the “subnational wizard” to create separate
population project files for urban and rural strata.9
The LiST provides estimates of the rates of still-
births, neonatal and infant mortality, and birth
outcomes (LBW, SGA, and preterm) by drawing
on population estimates from UNDP and other
data sources for mortality and birth outcome cal-
culations (Table 1). To permit estimation of the
marginal benefit of replacing IFA with MMS, we
created separate LiST projections for both country
case studies assuming either 100% IFA coverage
or current IFA coverage (for Bangladesh 50.3%
nationally, 60.7% urban, 47.4% rural; for Burkina
Faso 10.2% nationally, 16.0% urban, 8.4% rural).b
Werelied on a recentmeta-analysis by Smith et al.
for effect sizes for the marginal impacts of MMS,
compared with IFA, on mortality and birth out-
comes because the analysis examined both overall
effects and effects among selected subgroups, such
as anemic versus nonanemia women.6 We focused
on the following outcomes: stillbirths, mortality
among live births (neonatal and infant mortality;
6-month mortality was excluded because baseline
estimates were not available from LiST), very LBW,
LBW, very preterm birth, preterm birth, and small-
for-gestational age (SGA). Following Smith et al.,6
we estimated the effects on SGA using both Oken
and Intergrowth standards.c We did not include
bLiST projections were generated using version 5.63 of
LiST, which includes an effect of IFA on SGA. An updated
version of the tool (version 5.71) does not include an effect
of IFA on birth outcomes. All future simulations will be
run in SAS and using the results of Spectrum version
5.7; cross-model comparisons confirm that all differences
in the results generated by the Microsoft Excel and SAS
models are driven exclusively by the different versions of
the Spectrum software on which the models depend.
cLiST uses the Alexander standard to define SGA.
estimates of the effects on LGA because baseline
estimates are not available in LiST, and LGA is
not considered a desirable outcome. (We note that
although Smith et al. observed an increased risk of
LGA in themultiplemicronutrient group compared
with the IFA group using the Intergrowth standard,
but not the Oken reference, no increased risk of
mortality was observed.)
A recent Cochrane review reported slightly dif-
ferent estimates of the overall effect of MMS com-
pared with IFA, particularly for preterm birth and
stillbirth.10 For this analysis, we applied overall esti-
mates from Smith et al. for consistency with the
modeling of subgroup effects, but we note that
the overall effects on preterm birth, mortality, and
DALYs would be lower if the estimates from the
Cochrane review were used.
Outcomes were estimated only where the
marginal effect of MMS versus IFA was statisti-
cally significant (P < 0.05), either for the overall
analysis or for a given subgroup (in the case of
statistically significant effect modification). We
calculated the impacts of MMS in two ways: by
applying the overall effect size to the entire popula-
tion, and by incorporating effect modification (i.e.,
differing effects in different population subgroups)
by applying subgroup-specific effect sizes to the
appropriate subset of the population, and summing
these results within each stratum. For example,
within each stratum, the number of cases of LBW
averted by replacing IFA with MMS was calculated
separately for births to women with and without
anemia; results for each stratum (urbanmale, urban
female, etc.) were then summed to calculate the
total cases of LBW averted.
Smith et al. examined various potential effect
modifiers, some of which are potentially associ-
ated with each other (e.g., maternal hemoglobin at
enrollment and the presence of a skilled birth atten-
dant (SBA)). We applied the following selection
process to identify the final set of effect modifiers
(population subgroups) to be included in the anal-
ysis. First, effect modifiers for which the P value
for heterogeneity was >0.05 (on the basis of anal-
yses in Smith et al.6) were excluded for that out-
come. For example, the effect of MMS compared
with IFA on preterm birth did not differ by infant
sex (RR (95%CI);male 0.93 (0.88, 0.97); female 0.91
(0.86, 0.96); P for heterogeneity = 0.63, using data
from all trials). Remaining effect modifiers were
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Table 1. Population size, prevalence of effect modifiers for the marginal effect of MMS on mortality and birth out-
comes, and baseline burden of natural outcomes for Bangladesh and Burkina Faso in 2018, assuming current cov-
erage of iron-folic acid tablets in pregnancya
Bangladesh Burkina Faso
Urban Rural Urban Rural
Total population,b n 66,217,830 99,776,312 6,531,635 12,838,193
Population of age 0–4 years, n 4,966,020 10,072,979 715,465 2,348,602
Total annual births, n 1,101,038 1,898,474 158,552 521,623
Male births, % 51.19 51.19 51.1 51.1
Maternal anemia, % 31.4 43.2 58.9 70.9
Maternal underweight, % 16 28 8 18
Presence of a skilled birth attendant, % 75.7 32.4 93.9 61.8
Life expectancy at birth for males,c years 71.8 70.6 61.3 57.2
Life expectancy at birth for females, years 75.1 74.1 62.7 58.9
Stillbirth rate,d deaths per 1000 live births 4.78 21.17 2.89 20.32
Early neonatal mortality rate,e deaths per 1000 live birthsb 10.87 21.76 10.41 19.15
Neonatal mortality rate, deaths per 1000 live births 12.94 25.91 18.75 34.47
Infant mortality rate,f deaths per 1000 live births 24.5 34.4 39.1 72.2
Low birth weight,g % 20.93 21.66 13.86 14.00
Very low birth weight,h % 0.42 0.43 3.91 3.95
Preterm and SGA births,i % 2.57 2.68 1.84 1.87
Preterm and AGA births, % 10.85 10.85 9.14 9.14
Term and SGA births, % 30.15 31.46 20.12 20.43
Term and AGA births, % 56.43 55.01 68.90 68.56
aSource: LiST model, assuming current iron-folic acid coverage (Bangladesh: 60.7% in urban areas and 47.4% in rural areas; Burkina
Faso: 16.0% urban and 8.4% rural) and 0% coverage of multiple micronutrient supplements. In the LiST projection assuming 100%
coverage, birth outcome percentages are adjusted by internal algorithms to be the same for both rural and urban areas, which generate
slightly different population estimates.
bWithin LiST, population is estimated to be consistent with the censuses (1961, 1974, 1981, 1991, 2001, and 2011 in Bangladesh;
and 1985, 1996, and 2006 in Burkina Faso) adjusted for underenumeration, and with estimates of the subsequent trends in fertility,
mortality, and international migration. For Bangladesh, annual total population estimates from the Sample Vital Registration System
through 2014 were also considered, as well as the 2008 voter registration for adults age 18 and over.
cFor Bangladesh, life expectancy was based on life tables derived from age and sex-specific mortality rates from the Sample Vital
Registration System from 1981 up to 2015 adjusted for infant and child mortality, the 1974 Retrospective Survey of Fertility and
Mortality, and the 1962/65 Population Growth Estimation Experiment. Estimates are consistent with those from the 2001 and 2010
Bangladesh Maternal Mortality Surveys (based on sibling histories and household deaths in the preceding 36 months), and data
gathered from Matlab Health and Demographic Surveillance System up to 2012. For the period 1970–1975, mortality was adjusted
to take into account the excess mortality associated with the 1971 civil war and independence from Pakistan, and the 1974 flood
and famine. For Burkina, life expectancy was estimated using the South model of the Coale–Demeny Model Life Tables and three
parameters:1,2 direct and indirect estimates of infant and child mortality, and3 adjusted estimates of adult mortality (45q15). Data
from West African rural demographic surveillance sites and urban vital registration were also considered. Adjusted estimates of
adult mortality were derived from recent household deaths data (unadjusted and adjusted for underregistration using the growth-
balance and synthetic-extinct generationmethods) from the 1960/1961 survey, 1976, 1985, 1996, and 2006 censuses, the 1991National
Demographic Survey, and 2008 Global Fund survey; parental orphanhood from the 1993, 2003, and 2010/2011 DHS, 2006 MICS3
and 2006 census; siblings deaths from the 1998/1999, 2003, and 2010/11 DHS; intercensal survivorship from successive census age
distributions (smoothed and unsmoothed) for periods 1976–1985, 1985—1996, and 1996–2006; and the implied relationship between
child mortality and adult mortality based on the North model of the Coale–Demeny Model Life Tables in 1950–1955, and assumed
to converge over time toward the South model of the Coale–Demeny Model Life Tables by the 1990s.
dWHO estimates for years 2000–2015 (http://datacompass.lshtm.ac.uk/115/).
eLiST does not report early neonatal mortality rates. However, Rahman Chowdhury et al.20 report that the early neonatal mortality
rate in Bangladesh is 84%of the total neonatalmortality rate (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2965329/), andKoueta
et al.21 report that the early neonatal deaths in Burkina Faso account for 55.6% of the total neonatal mortality.
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discussed on a case-by-case basis for each outcome,
with consideration given to the (1) independence of
effectmodifiers, for example, the presence of an SBA
and maternal adherence to supplementation may
be influenced by similar factors; (2) availability of
data on prevalence of effect modifiers, for example,
gestational age at enrollment in the trial (initiation
of supplementation) is information that would be
available in a clinical trial setting but typically not in
a programmatic or national distribution setting; and
(3) potential for translating effect modifiers from
clinical trial settings to a program setting, for exam-
ple, adherence is assessed in trial settings but is not
always assessed in the context of programs. Addi-
tional details on this selection process, which apply
to both the Bangladesh and Burkina Faso case stud-
ies, are presented in Supplementary Tables S1 and
S2 (online only).
Thus, for example, for female infants, a 14%
reduction in early neonatal mortality was applied
(RR = 0.86, from Smith et al.6), but no cases of
early neonatal mortality were averted among male
infants. For infant mortality, two effect modifiers
were selected: infant sex and the presence of an SBA.
In this case, we applied the following reductions in
infant mortality to each subgroup: male, with SBA:
0 effect; female, with SBA: 13% reduction (RR =
0.87); males and females without SBA: 18% reduc-
tion (RR = 0.82).
We used results from all trials included in the
Smith et al.meta-analysis for our primary analysis.
As a sensitivity analysis, we also calculated results
using effect sizes from the subset of trials in which
the multiple micronutrient and IFA supplements
contained equal doses of iron (n= 8 trials). See Sup-
plementary Tables S4 and S6 (online only) for these
results for Bangladesh, and Supplementary Tables
S5 and S7 (online only) for Burkina Faso.
Data sources and assumptions: DALYs
We calculated DALYs according to the method
proposed by Fox-Rushby and Hanson11 and Mur-
ray and Lopez12 without age weighting. We gen-
erated separate estimates for YLL due to mortality
(including stillbirth and postnatal mortality), dis-
ability due to LBW, and disability due to preterm
birth. Because the mortality estimates included in
the cost-effectiveness analysis (neonatal, 6-month,
and infant mortality) are not independent, we cal-
culated YLL using infant mortality rates in addi-
tion to stillbirths, which are estimated separately in
LiST, and applied stratum-specific life expectancy
estimates (Table 1).
Table 1. Continued
f Infant mortality estimates are derived from the child mortality rates using the West model of the Coale–Demeny Model Life Tables
and are consistent with national estimates. Childmortality estimates are based on (1) adjusted data from the Sample Vital Registration
System from 1980 through 2015, (2) data on children ever-born and surviving classified by age of mother (and the West model of
the Coale–Demeny Model Life Tables), and (3) data on births and deaths under-five calculated from maternity-history data from
the 1993/1994, 1996/1997, 1999/2000, 2004, 2007, 2011, and 2014 DHS, 2001 Bangladesh Maternal Health Services and Maternal
Mortality Survey, 2009 MICS, and 2012/2013 MICS (preliminary). Levels and trends since the mid-1980s are consistent with under-
five mortality estimates on the basis of the 2001 BMMS sibling history and data gathered from Matlab Health and Demographic
Surveillance System up to 2005. In Burkina Faso, estimates of infant mortality are based on (1) data on births and deaths under-five
frommaternity-history data from the 1992/1993, 1998/1999, 2003DHS, and 2010/11DHS-MICS; (2) data on recent household deaths
from the 1960/1961 survey, 1976, 1985, 1996, and 2006 censuses, and the 1991 National Demographic survey; (3) data on children
ever-born and surviving classified by age of mother (and the North model of the Coale–Demeny Model Life Tables) from these data
sources as well as from the 2006 MICS3 survey. Infant mortality estimates are cross-validated and adjusted for underreporting using
relationships between infant and child mortality estimates (for both sexes, and by sex) using data from 15 demographic surveillance
sites and cohort studies in the Sahel region for the period 1943–1999.
gThe burden of low birth weight in Burkina Faso may be biased because only approximately one third of children are weighed several
days (or more) after birth (Blanc and Wardlaw22). However, the direction of the bias is challenging to assess for at least two reasons:
heavier children are more likely to survive to be weighed, but children are known to lose body weight during the first few days after
birth.
h LiST does not report very low birth weight rates. However, the National Low Birth Weight Survey of Bangladesh reports that
approximately 2% of Bangladeshi infants born with low birth weight (<2500 g) have very low birth weight (<1500 g) (https:
//www.unicef.org/bangladesh/Low_Birth_Weight_report.pdf), and Villani et al.23 report that approximately 28.2% of Burkina Faso
infants born with low birth weight have very low birth weight.
i For details, see Lee et al.24
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The Global Burden of Disease study reports
disability weights for different consequences of
preterm birth (vision, cognitive, motor, epilepsy
alone or epilepsy combined with motor or cogni-
tive impairments),13 but there is only one disability
weight covering LBW and its consequences (from
previous work12) and no disability weight for SGA.
Therefore, for LBW, total DALYs were calculated,
and for preterm birth, DALYs were estimated using
several preterm birth sequelae and their estimated
severities (Supplementary Table S3, online only).
The same sequelae-specific disability weights were
used for the Bangladesh and the Burkina Faso case
studies.
The proportion of the population affected by
each condition (consequence of preterm birth) was
based on estimates provided by several papers.
We did not estimate YLDs for vision impairments
due to preterm birth.14,d For Bangladesh, the pro-
portions of the population affected by each level
of severity (i.e., the proportion with mild, mod-
erate, or severe impairment) were based on esti-
mates for severity of motor impairment by Benfer
et al.15 For Burkina Faso, estimates of the same pro-
portions were provided by Ogoke and Iloeje16 for
the case of Nigeria, which we then assume apply
to the population of preterm children in Burkina
Faso.
For both case studies, we assume that the con-
sequences of preterm birth and LBW will begin
in the first year of life and persist throughout an
affected individual’s lifetime, and therefore applied
the respective disability weight to the country- and
stratum-specific life expectancy of each affected
individual (Table 1).
Finally, because LBW and preterm are not inde-
pendent outcomes, we calculated total DALYs by
combining YLL from stillbirth and infant mor-
tality, YLDs from LBW, and YLL from stillbirth
and infant mortality, and YLDs from preterm
birth.
dBlencowe et al.14 estimate the share of the population
affected on the basis of the presence of neonatal inten-
sive care units (NICU) because rates of retinopathy of
prematurity (ROP) are dependent on the quality of care
received.Access toNICU inBangladesh andBurkina Faso
is low, and the share of the population affected by ROP is
estimated to be very small.
Data sources and assumptions: tablet costse
Wecalculated the cost of replacing IFAwithMMSas
the marginal cost of multiple micronutrient tablets
compared with IFA tablets and did not consider
the cost for production of capsules instead of
tablets.f We focus only on production costs, assum-
ing that packaging, transportation, in-country ship-
ping/handling, and other costs would be very simi-
lar to those that countries are paying or would have
to pay for importing and distributing IFA tablets.
The micronutrient ingredient cost of a standard
UNIMMAP formulationg is roughly twice that of an
IFA tablet containing 60 mg of iron and 400 µg of
folic acid, and about three times that of an IFA tablet
containing 30 mg of iron and the same amount
of folic acid.h We estimate that producing multi-
ple micronutrient tablets using the UNIMMAP for-
mula would cost approximately $US 0.004878 more
than producing a tablet that contains the average
amount of iron included in currently available IFA
tabletsi and 400 µg of folic acid. This translates into
a marginal increase in tablet costs of $US 4878 per
million tablets. This marginal cost ignores all costs
associated with, for example, changes in packag-
ing that an IFA-MMS switch might require. In this
analysis, we are examining the benefits and costs
of an immediate, complete, 1-year switch from IFA
eVery few low-income countries have the national capac-
ity to produce the quantities or qualities of multiple
micronutrient tablets that would be required to replace
IFA tablets. Therefore, in this analysis, all costs are based
on tablets produced in Europe.
fThis analysis focuses exclusively on IFA and multiple
micronutrient tablets. These micronutrients can also be
delivered in the form of capsules, which are expected to
cost approximately 10% more than tablets (K. Kramer,
2018. Personal communication).
gThe commonly used UNIMMAP formulation includes
the followingmicronutrients: iron (mg) 30; folic acid (µg)
400; Vit A (µg) 800; Vit D (IU) 200; Vit E (mg) 10;
Vit C (mg) 70; Vit B1 (mg) 1.4; Vit B2 (mg) 1.4; niacin
(mg) 18; Vit B6 (mg) 1.9; Vit B12 (µg) 2.6; zinc (mg)
15; copper (mg) 2; selenium (µg) 65; iodine (µg) 150
(UNICEF/WHO/UNU 1999).
hK. Kramer, 2018. Personal communication.
i There is some uncertainty around the quantity of iron
thatwill be included inmultiplemicronutrient tablets. For
cost analyses presented here, we used an average of the
amounts of iron ((60 mg + 30 mg)/2 = 45 mg) in com-
monly available IFA tablets.
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Table 2. Estimated costs of replacing IFA tablets with multiple micronutrient tablets in Bangladesh and Burkina
Faso, assuming 100% coverage, or current coveragea
Bangladesh Burkina Faso
100% coverage Current coverage 100% coverage Current coverage
Urban Rural Urban Rural Urban Rural Urban Rural
Annual births
(live births +
stillbirths), n
1,106,845 1,938,651 1,106,305 1,938,665 159,010 532,224 159,010 532,224
Proportion of births
covered, %
100 100 60.7 47.4 100 100 16.0 8.4
Number of tablets
consumed per
covered birth, n
180 180 180 180 180 180 180 180
Total number of
tablets distributed
annually, n
199,232,100 348,957,180 120,874,884 165,406,898 28,621,800 95,800,320 4,579,488 8,047,227
Total annual
incremental tablet
cost, USD
$971,921 $1,702,330 $589,668 $806,910 $137,262 $459,433 $21,924 $38,525
aCurrent coverage was estimated to be as follows: Bangladesh: 60.7% in urban areas and 47.4% in rural areas; Burkina Faso: 16.0%
urban and 8.4% rural.8
Note: Costs are the incremental cost of the supplements ($US 0.004878 per tablet, assuming imported tablets) and exclude program-
matic transition costs and tablet “waste” (i.e., in this analysis, the appropriate numbers of tablets are distributed and are consumed).
We used the sum of live births and stillbirths as a proxy to estimate the annual number of pregnancies. This underestimates the
number of pregnancies, since miscarriages and elective terminations of pregnancies are not included.
to MMS, and therefore do not address the pro-
grammatic costs of a (likely) multiyear transition,
for example, costs of meetings related to advocacy
and logistics, and additional health worker training.
These issues will be explored in future work.
For both country’s case studies, the total number
of tablets consumed was estimated by calculating
the total number of annual births as the sum of live
births and stillbirths (excluding miscarriages and
elective terminations) and multiplying this number
by the assumed number of tablets consumed per
pregnancy (180) and program coverage. Tablet cost
differentials are reported below in $US.
Results
Population characteristics and baseline
burden of natural outcomes
The baseline information required to estimate the
effects of shifting from IFA to MMN, for urban
and rural populations in Bangladesh and Burkina
Faso, appears in Table 1. Rates of stillbirth and post-
natal mortality, and prevalence of birth outcomes
were estimated using the LiSTmodel; mortality was
generally greater in rural areas although estimated
prevalence of birth outcomes did not differ. The
prevalence of population subgroups with different
responses to shifting from IFA to MMS also var-
ied between urban and rural strata. For example, in
the rural stratum, the prevalence of maternal ane-
mia and maternal underweight was greater, and the
prevalence of presence of an SBA was lower.
The size and age structure of the Burkinabe
population are very different from those of the
Bangladeshi population; both population charac-
teristics will affect the overall benefits and costs of
shifting from IFA to MMS. Note also that child
mortality rates and rates of undesirable birth out-
comes vary substantially across the two case study
countries. Therefore, the composition of the bene-
fits of shifting from IFA to MMS is expected to vary
between the two countries.
Estimated tablet costs
In the hypothetical scenario for Bangladesh, in
which all pregnant women receive and consume 180
tablets and 100% of IFA tablets are replaced with
MMS, ∼550 m tablets would be consumed annu-
ally, and the additional cost to replace the IFA tablets
would be $US 2.7 million (Table 2). At current
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coverage levels (∼50%, nationally), the cost would
be $US 1.4 million, assuming 180 tablets per cov-
ered pregnancy.
In Burkina Faso, if all pregnant women receive
and consume 180 tablets and 100% of IFA tablets
are replaced with MMS, ∼125 m tablets would be
consumed annually at an additional cost of approx-
imately $US 600,000 (Table 2). At current cover-
age levels (10.2% nationally, 16% in urban areas and
8.4% in rural areas), many fewer tablets (∼12.6 m)
would be needed and the cost would be substantially
lower (approximately $US 60,000).j
Predicted effects and cost-effectiveness for
mortality and birth outcomes
Table 3 reports the predicted additional benefits in
Bangladesh of replacing IFA with MMS in relation
to cases of mortality averted and other adverse birth
outcomes averted. These benefits are substantial for
the 100% coverage scenario, but remain so even in
the case of the current coverage scenario (∼50%
nationally: 61% in urban areas, 47% in rural areas,
WFP/UNICEF/IPHN, 2009).
If all pregnant women consumed the prescribed
number of tablets, replacing IFAwithMMSwas pre-
dicted to reduce the number of stillbirths by more
than 3600 cases, whereas current coverage levels
could still be expected to yield 1780 cases of still-
birth averted if each covered woman took the full
course of supplements. Although the overall impact
of MMS compared with IFA on infant mortality
was not statistically significant (Smith et al.6), a
significant reduction in infant mortality would be
expected to occur among female infants and births
at which no SBA was present. Accounting for these
jThe roughly linear relationship between coverage and the
tablet needs and costs of shifting from IFA toMMS in the
context of this single-year, immediate-switch experiment
is to be expected—low-coverage IFA programs are less
expensive to convert to MMS because fewer tablets are
distributed. However, the role of program performance
in determining the cost-effectiveness of making the shift
from IFA to MMS will become apparent when the (1)
timeframe for analysis is extended, (2) transition costs
are incorporated, and, in particular, (3) marginal costs of
tablets consumed below and in excess of the prescribed
180-tablet protocol are included. We will address all of
these issues in future work.
subgroup effects, by replacing IFAwithMMS, infant
mortality would fall by 5848 at current coverage and
by 11,646 with 100% coverage.
The predicted additional benefits for the case
of Burkina Faso of replacing IFA with MMS are
very different from those of Bangladesh (Table 4).
Although birthrates are much higher in Burk-
ina Faso, the population in Bangladesh is much
larger than that of Burkina Faso, so all estimates
of the absolute benefits for Burkina Faso are much
smaller. In addition, as noted earlier, rates of child
mortality are in general higher, and of undesired
birth outcomes lower, in Burkina Faso than in
Bangladesh.
In Burkina Faso, replacing MMS with IFA
(assuming 180 tablets per covered pregnancy)
was predicted to reduce the number of stillbirths
by 885 cases, whereas current coverage levels are
expected to yield only 77 cases of stillbirth averted.
Accounting for heterogeneity in the effects of MMS
versus IFA on infant mortality, replacing IFA with
MMS would reduce infant mortality by 407 cases
in 2018 at current coverage and by 4457 with 100%
coverage.
Accounting for effect modification only slightly
modified the number of cases of preterm and
SGA avoided. However, the number of cases of
SGA avoided was almost twice as high when using
effect sizes for the Intergrowth standard compared
with the Oken reference (assuming 100% cover-
age, Bangladesh: 42,922 Intergrowth versus 25,753
Oken; Burkina Faso: 6505 Intergrowth versus 3903
Oken).
For both countries, the number of cases of mor-
tality or adverse birth outcomes averted in the
current coverage scenario was approximately pro-
portional to the number of cases averted in the
100% coverage scenario (i.e., approximately half
in Bangladesh and ∼10% in Burkina Faso). How-
ever (predictably, in this analysis), the cost per case
averted was very similar since only the marginal
cost of tablets was included and we assumed 100%
adherence among covered pregnancies and no
waste in the distribution of tablets.
In Bangladesh (Table 3), the predicted cost per
death averted ranged from ∼US$239 (infant mor-
tality, with effect modification) to ∼US$785 (still-
births, overall effect), or∼US$184 per death averted
in total (stillbirths + infant mortality); equiva-
lent values for Burkina Faso (Table 4) ranged
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Table 3. Marginal benefits of replacing IFA tablets with multiple micronutrient tablets for pregnant women in
Bangladesh: number of cases of stillbirths, mortality, and adverse birth outcomes averted in 2018, andUSD per case
averted, assuming either 100% coverage or current coverage (∼50%) and using estimated overall marginal effects of
MMS over IFA from all trials, and incorporating effect modification of the relationship between supplementation
and the selected outcomesa
Number of cases averted
annually USD per case averted
100% coverage
Current
coverage 100% coverage
Current
coverage
Stillbirths Overall effect 3637 1780 $735.31 $784.61
Effect modifier (n/a) No EM No EM No EM No EM
Early neonatal Overall effect 0 0 n/a n/a
mortality Effect modifier (infant sex) 3587 1809 $745.44 $772.21
Neonatal mortality Overall effect 0 0 n/a n/a
Effect modifier (infant sex) 4576 2307 $584.43 $605.41
Infant mortality Overall effect 0 0 n/a n/a
Effect modifier (infant sex and the
presence of skilled birth attendant)
11,646 5848 $229.62 $238.79
Low birth weight Overall effect 67,807 35,452 $39.44 $39.39
Effect modifier (maternal anemia) 68,579 37,869 $38.99 $36.88
Very low birth weight Overall effect 2486 1300 $1075.62 $1074.37
Effect modifier (n/a) No EM No EM No EM No EM
Very preterm birth Overall effect 6641 3472 $402.67 $402.21
Effect modifier (maternal underweight) 3555 1804 $752.31 $774.33
Preterm birth Overall effect 31,438 16,437 $85.06 $84.97
Effect modifier (maternal underweight) 33,007 17,112 $81.02 $81.62
SGA Oken Overall effect 25,753 13,465 $103.84 $103.72
Effect modifier (n/a) 21,541 13,710 $124.15 $101.87
SGA Intergrowth Overall effect 42,922 22,441 $62.31 $62.23
Effect modifier (n/a) No EM No EM No EM No EM
Total mortality
(stillbirths + infant
mortality)
Varied (no EM for stillbirth; infant sex
and the presence of skilled birth
attendant for infant mortality)
15,283 7628 $174.98 $183.08
aResults assume that each pregnant woman who is covered receives and consumes 180 capsules per pregnancy and that tablets are
imported.
Note: Effect sizes for estimation of cases averted are taken from Smith et al.,6 using results from all included trials. See the text for
explanation of selection of effect modifiers for each outcome.
EM, effect modification; IFA, iron-folic acid; SGA, small for gestational age; n/a, maternal anemia.
from ∼US$148 (infant mortality, with effect mod-
ification) to ∼US$784 (stillbirths, overall effect)
and ∼US$125 per death averted in total. For
adverse birth outcomes, the cost per case averted in
Bangladesh ranged from ∼US$37 per case of LBW
averted (with effect modification) to∼US$1074 per
case of very LBWaverted (overall effect). In Burkina
Faso, the cost per case averted ranged from∼US$44
per case of LBW averted (with effect modification)
to ∼US$797 per case of very preterm birth averted
(overall effect).
Predicted effects and cost-effectiveness of
shifting from IFA to MMS for YLL,YLD, and
DALYs averted
Predicted numbers of YLL, years lived with disabil-
ity (YLD), and DALYs averted by shifting from IFA
to MMS for Bangladesh and Burkina Faso are pre-
sented in Tables 5 and 6, respectively, using over-
all effects and accounting for effect modification
(subgroup effects), for both the 100% coverage and
for the current coverage scenarios. In Bangladesh,
estimated effects for the ∼50% current coverage
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Table 4. Marginal benefits of replacing IFA tabletswithmultiplemicronutrient tablets for pregnantwomen inBurk-
ina Faso: number of cases of stillbirths, mortality, and adverse birth outcomes averted in 2018, and USD per case
averted, assuming either 100% coverage or current coverage (∼10%) and using estimated overall marginal effects of
MMS over IFA from all trials, and incorporating effect modification of the relationship between supplementation
and the selected outcomesa
Number of cases averted
annually USD per case averted
100%
coverage
Current
coverage
100%
coverage
Current
coverage
Stillbirths Overall effect 885 77 $674.45 $784.03
Effect modifier (n/a) No EM No EM No EM No EM
Early neonatal Overall effect 0 0 n/a n/a
mortality Effect modifier (infant sex) 778 74 $767.18 $819.62
Neonatal mortality Overall effect 0 0 n/a n/a
Effect modifier (infant sex) 1500 142 $397.79 $424.99
Infant mortality Overall effect 0 0 n/a n/a
Effect modifier (infant sex and the
presence of skilled birth attendant)
4457 407 $133.88 $148.41
Low birth weight Overall effect 10,320 1050 $57.82 $57.59
Effect modifier (maternal anemia) 7740 1369 $50.88 $44.16
Very low birth weight Overall effect 5336 543 $111.83 $111.38
Effect modifier (n/a) No EM No EM No EM No EM
Very preterm birth Overall effect 2513 240 $237.44 $251.58
Effect Modifier (maternal underweight) 871 76 $684.73 $797.37
Preterm birth Overall effect 5846 595 $102.07 $101.66
Effect modifier (maternal underweight) 5520 551 $108.09 $109.69
SGA Oken Overall effect 3903 397 $152.89 $152.28
Effect modifier (n/a) 4825 704 $123.66 $85.88
SGA Intergrowth Overall effect 6505 662 $91.74 $91.37
Effect modifier (n/a) No EM No EM No EM No EM
Total mortality
(stillbirths + infant
mortality)
Varied (no EM for stillbirth; infant sex
and the presence of skilled birth
attendant for infant mortality)
5342 484 $111.71 $124.79
aResults assume that each pregnant woman who is covered receives and consumes 180 capsules per pregnancy and that tablets are
imported.
Note: Effect sizes for estimation of cases averted are taken from Smith et al.,6 using results from all included trials. See the text for
explanation of selection of effect modifiers for each outcome.
EM, effect modification; IFA, iron-folic acid; SGA, small for gestational age; n/a, maternal anemia.
scenario were approximately half those estimated
in the hypothetical 100% coverage scenario; total
predicted DALYs averted at 100% coverage ranged
from ∼209,200 (DALYs estimated using YLL +
preterm YLD, overall effect of MMS) to ∼747,500
(DALYs estimated using YLL + LBW YLD, with
effect modification). YLL constituted 34% and 57%
of total DALYs estimated using LBW and preterm,
respectively, when overall effects were applied, and
68% and 84% of total DALYs when effect modifica-
tion was taken into account. The predicted cost per
YLL, YLD, and DALY averted was almost identical
between the two coverage scenarios, with the cost
per DALY averted∼US$7–13 for overall effects and
US$3–5 when accounting for effect modification.
In Burkina Faso (Table 6), for all summary bene-
fit measures, current (∼10%) coverage rates of IFA
(and by assumption, multiple micronutrient) pro-
grams are very low relative to 100% coverage esti-
mates, but again, cost-effectiveness estimates were
roughly similar because of the single-year, tab-cost-
only focus of this analysis. That said, under cur-
rent coverage, the cost per DALY averted by shifting
from IFA to MMS in the context of Burkina Faso
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Table 5. Marginal benefits of replacing IFA tablets with multiple micronutrient tablets for pregnant women
in Bangladesh: disability-adjusted life-years (DALYs), and USD per DALY averted in 2018, assuming either
100% coverage or current coverage (∼50%) and using estimated overall marginal effects of MMS over IFA from
all trials and incorporating effect modification of the relationship between supplementation and the selected
outcomesa
Number of YLL, YLD, or
DALYs averted
USD per YLL, YLD, or DALY
averted
100%
coverage
Current
coverage
100%
coverage
Current
coverage
YLL (mortality) Overall effect 118,824 58,142 $22.51 $24.02
Effect modifier (multiple) 510,386 254,708 $5.24 $5.48
YLD (low birth weight) Overall effect 234,378 122,486 $11.41 $11.40
Effect modifier (maternal
anemia)
237,083 130,861 $11.28 $10.67
YLD (preterm birth) Overall effect 90,414 47,250 $29.58 $29.56
Effect modifier (maternal
underweight)
94,653 49,067 $28.25 $28.46
Total (mortality + LBW) Overall effect 353,202 180,628 $7.57 $7.73
Effect modifier (multiple) 747,469 385,569 $3.58 $3.62
Total (mortality + preterm) Overall effect 209,238 105,392 $12.78 $13.25
Effect modifier (multiple) 605,036 303,775 $4.42 $4.60
aResults assume that each pregnant woman who is covered receives and consumes 180 capsules per pregnancy and that tablets are
imported.
Note: Effect sizes for estimation of cases averted are taken from Smith et al.,6 using results from all included trials. See the text for
explanation of selection of effect modifiers for each outcome.
DALY, disability-adjusted life year; YLD, years lived with disability; YLL, years of life lost.
was similar to that for Bangladesh, ranging from
approximately US$3 to US$15.
Sensitivity analyses
Results for mortality and birth outcomes, and for
summary YLL, YLD, and DALY averted, were sim-
ilar when effect sizes from the meta-analysis lim-
ited to trials in which equal doses of iron were used
in the IFA and multiple micronutrient groups were
applied (Supplementary Tables S4 and S6, online
only, for the case of Bangladesh, and Supplemen-
tary Tables S5 and S7, online only, for Burkina Faso).
Sensitivity analyses of the cost per YLL and total
DALYs averted associated with changes in assumed
tablet costs are presented in Supplementary Table S8
(online only) for Bangladesh and in Supplementary
Table S9 (online only) for Burkina Faso. Under the
assumptions of this analysis (180 tablets per cov-
ered pregnancy), changes in the cost per YLL and
DALY averted were proportional to changes in the
incremental tablet cost (i.e., doubling the incremen-
tal cost per tablet would double the cost per DALY
averted).
Discussion
Policymakers in LMICs are aware that women of
reproductive age in general, and pregnant women
in particular, are lacking in some of the micronu-
trients that are essential for healthy pregnancies
and healthy infants. One method for addressing
thesemicronutrient deficiencies is the shift from the
decades-long practice of providing IFA to pregnant
women to providing multiple micronutrient tablets
that contain iron, folic acid, and an array of other
micronutrients. In this study, we developed a model
to provide estimates of the expected benefits and the
expected costs of such a transition in the very dif-
ferent contexts of Bangladesh and Burkina Faso, if
done immediately in both cases for 1 year, and if the
only additional cost were that associated with pur-
chasing the more expensive multiple micronutrient
tablets.
The expected benefits of the shift from IFA
to MMS are substantial, both with reference to
reductions of mortality and undesirable birth out-
comes (e.g., LBW). Under the assumption that all
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Table 6. Marginal benefits of replacing IFA tablets with multiple micronutrient capsules for pregnant women
in Burkina Faso: disability-adjusted life-years (DALYs), and USD per DALY averted in 2018, assuming either
100% coverage or current coverage (∼10%) and using estimated overall marginal effects of MMS over IFA from
all trials and incorporating effect modification of the relationship between supplementation and the selected
outcomesa
Number of YLL, YLD, or
DALYs averted
USD per YLL, YLD, or DALY
averted
100%
coverage
Current
coverage
100%
coverage
Current
coverage
YLL (mortality) Overall effect 27,697 2412 $21.54 $25.06
Effect modifier (multiple) 171,190 15,510 $3.49 $3.90
YLD (low birth weight) Overall effect 34,197 3474 $17.45 $17.40
Effect modifier (maternal
anemia)
38,865 4531 $15.35 $13.34
YLD (preterm birth) Overall effect 15,372 1562 $38.82 $38.71
Effect modifier (maternal
underweight)
14,566 1454 $40.97 $41.58
Total (mortality + LBW) Overall effect 61,894 5887 $9.64 $10.27
Effect modifier (multiple) 210,055 20,042 $2.84 $3.02
Total (mortality + preterm) Overall effect 43,069 3974 $13.85 $15.21
Effect modifier (multiple) 185,756 16,964 $3.21 $3.56
aResults assume that each pregnant woman who is covered receives and consumes 180 capsules per pregnancy and that tablets are
imported.
Note: Effect sizes for estimation of cases averted are taken from Smith et al.,6 using results from all included trials. See the text for
explanation of selection of effect modifiers for each outcome.
YLD, years lived with disability; YLL, years of life lost.
pregnant women are treated with a regimen of 180
tablets consumed over their pregnancies, shifting
from IFA toMMSwas predicted to save over 15,000
young lives in 1 year in Bangladesh (combining
stillbirths and infant mortality) and approximately
30,000 cases of preterm birth would be averted.
In all, ∼600,000 DALYs would be averted from a
1-year switch. Most of these measures of impact
are reduced by approximately one-half if current
coverage of the IFA program (∼50% nationally) is
imposed in the model. Nonetheless, even at current
coverage levels, the savings in lives and in YLDs are
expected to be substantial in Bangladesh if adher-
ence to the prescribed number of tablets is high.
The expected benefits of shifting from IFA to
MMS in the context of Burkina Faso are much
smaller, in part because the overall population is
smaller but also because the current coverage of the
IFA program is low (∼10% nationally).8 Under the
current-coverage scenario, the model predicts that
a 1-year shift from IFA to multiple micronutri-
ent tablets would save 484 young lives (stillbirth
and infant mortality) and eliminate over 550 cases
of preterm birth in that year, which would result
in ∼17,000 DALYs being avoided. Because current
coverage in Burkina Faso was estimated from DHS
data as the share of women who reported that they
took IFA supplements for 180 or more days during
their previous pregnancy, these are likely conserva-
tive estimates of the benefits of replacing IFA with
MMS in Burkina Faso. That is, approximately 40%
of women in Burkina Faso reported consuming at
least 90 but fewer than 180 IFA tablets, and any ben-
efits (and costs) of this level of consumption were
not captured in this analysis. On the other hand, the
results for Bangladeshmay overestimate the benefits
of this switch since the available definition of cover-
age did not specify a minimum number of tablets
consumed. However, it is important to note that the
cost-effectiveness of the outcomes examined did not
vary appreciably by coverage under this scenario.
That is, the absolute benefits of this programmatic
changewould increasewith increasing coverage, but
the relative value of investing in replacing IFA with
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MMS compared with other health investments does
not depend on coverage (under a scenario in which
the only costs are those of the tablets themselves
and all covered pregnancies are assumed to receive
and consume 180 tablets; as noted elsewhere, the
cost-effectiveness of varying numbers of tablets dis-
tributed and consumed will be examined in subse-
quent work).
The costs associated with shifting from IFA to
MMS will be significant, mainly because the mul-
tiple micronutrient tablets are approximately 35%
more expensive than IFA tablets and, in the con-
text of Bangladesh, hundreds of millions of tablets
would be required each year. In sum, the complete
and immediate shift from IFA to MMS for 1 year
in Bangladesh, given current coverage levels, would
be approximately US$1.7 million, but costs would
rise to US$2.7 million if sufficient tablets were pur-
chased to cover all pregnancies with 180 tablets per
person. In Burkina Faso,making the IFA-MMS shift
only for those currently receiving the full regimen
of tablets (at least 180 per person) would require
only approximately 12.5 m multiple micronutrient
tablets at an estimated cost of approximately US$
60,000; accounting for tablets distributed to women
who consumed less than 180 tablets during preg-
nancy would increase these costs.
The total (tablet) cost of shifting from IFA to
multiple micronutrient tablets will depend on the
negotiated prices of both types of tablets, which
will depend heavily on the volume and continu-
ity of purchasing agreements, which will simulta-
neously involve discussions with tablet ingredient
suppliers regarding the prices of the micronutri-
ents needed to produce them. For example, Vitamin
Angels, one of the largest international purchasers
of multiple micronutrient tablets, paid ∼0.010722
US$ per tablet (delivered, in 180-tablet contain-
ers, to their U.S.-based warehouses) in 2018. This
is a lower per-tablet cost than suggested by oth-
ers (e.g., 0.0111 US$ per tablet, including packag-
ing and USP certification, but not shipping).k Scale
economies in tablet production are very substan-
tial and developing countries may not have suffi-
cient demand or negotiating leverage to secure the
lowest possible tablet costs. The cost-effectiveness
of shifting from IFA to MMS will depend, in part,
kK. Kramer, 2018. Personal communication.
on the cost of multiple micronutrient tablets, which
will be negotiated outcomes. The sensitivity analy-
ses presented here explore the implications for cost-
effectiveness of these outcomes. For example, a 50%
reduction in themarginal tablet cost would increase
the cost-effectiveness from∼$3 to 15/DALYaverted
across the two countries to∼$2 to 8/DALY averted,
whereas a 50% increase in the marginal tablet
cost would reduce the cost-effectiveness to ∼$6 to
30/DALY averted.
Cost-effectiveness of this narrow, 1-year pro-
grammatic experiment suggests that this policy
change is worthy of consideration.l For example, the
cost per case of total mortality averted (considering
both stillbirths and infantmortality, and accounting
for subgroup effects for the latter) under current-
coverage scenarios in each country is approximately
US$183 in Bangladesh andUS$125 in Burkina Faso.
The cost-effectiveness of the IFA-MMS shift for
averting child mortality is generally favorable when
compared with other mortality-averting policy
options: for example, pneumococcus and rotavirus
vaccines in low-income countries tended to be
more cost-effective (from less than US$100/death
averted), while most other life-saving interven-
tions tended to be much less cost-effective (e.g.,
for rotavirus and HiB vaccines in lower-middle
income countries, over $1000 per death averted).17
In addition, training traditional birth attendants to
reduce mortality due to birth asphyxia, hypother-
mia, and neonatal sepsis in Zambia was estimated
to cost $591 per death averted in the optimistic
scenario and $1866 per death averted in the “base
case” scenario,18 and a package of interventions
including home visits for early neonatal care in
Bangladesh was estimated to cost $2939 per death
averted.19 The cost-effectiveness is also greater than
that estimated for other interventions targeted to
pregnant women. For example, women’s groups for
prenatal and newborn care were estimated to cost
more than $1000 per death averted.
lThat said, preliminary analyses involving programmatic
transition costs and inefficiencies, and especially of adher-
ence by women to the suggested IFA (and by assumption,
multiple micronutrient) protocol, on cost-effectiveness
estimates suggest that under some sets of assumptions,
costs per outcome or DALY averted could increase by
fourfold.
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Similarly, since most of the lives saved by shift-
ing from IFA toMMSwould occur very early in life,
by the summary measure of benefits, DALYs, this
policy action compares very favorably with most
alternatives in Bangladesh and Burkina Faso. In
current-coverage scenarios, the cost per DALY
averted by shifting from IFA to MMS ranges from
US$3.62 to US$13.25 in Bangladesh, and from
US$3.02 to US$15.21 in Burkina Faso, depending
on themethod used. These cost-effectiveness ranges
are comparable to those of other interventions that
save lives and reduce disability burdens, for exam-
ple, zinc plus oral rehydration (cost-effectiveness
range ∼US$10–US$80 per DALY averted).17
The analyses underlying the estimated benefits
and costs associated with shifting from IFA toMMS
presented here have several important limitations.
First, the analysis assumes a complete, immedi-
ate, and costless shift from IFA to MMN. This is
unlikely to be the case in any country and future
work will focus on the consequences for bene-
fits and costs of relaxing these assumptions. More
specifically, all transitions from IFA to MMS will
take time and require investments—all of these
costs will be faced up-front and will erode the
cost-effectiveness of shifting from IFA to multi-
ple micronutrient tablets. That said, in countries
where IFA programs are functioning well (i.e., with
high coverage rates), we expect the bulk of the
cost increases to reflect themore expensivemultiple
micronutrient tablets. However, in countries with
low-performing IFA programs, the benefits associ-
ated with shifting from IFA to multiple micronutri-
ent tablets could be attenuated by program transi-
tion costs.
Second, the analysis assumes that all “covered”
pregnant women receive and consume exactly 180
tablets, a threshold that is generally consistent with
the doses given in the trials that generated the mea-
sures of effect used in this analysis. It is reasonable
to expect that there may be benefits associated with
consumption of a smaller number of tablets (e.g.,
150 instead of 180), but existing data are insufficient
to construct a dose–response curve for number of
tablets consumed and each of the outcomes mea-
sured here. Thus, it was necessary to select a thresh-
old to apply the expected benefits of supplemen-
tation, recognizing that this approach may under-
estimate the benefits of multiple micronutrient
delivery.
Third, this analysis ignores other potential ben-
efits of multiple micronutrient provision for the
mother and child, such as correcting maternal
deficiencies in nutrients such as zinc or thiamin.
Instead, we relied on a recent meta-analysis for
estimates of the benefits of MMS versus IFA with
regard tomortality and adverse birth outcomes.Our
approach takes advantages of the rigorous evidence
base for these selected outcomes but may under-
estimate the overall benefits of replacing IFA with
MMS.
Finally, consumption by all covered women
of an exact dose of tablets will never be the
case programmatically—some women will con-
sume fewer than 180 tablets and others may con-
sume more than 180 tablets—in the current model,
in both cases, the costs of an IFA-to-multiple
micronutrient shift will increase, but the expected
benefits will not.m In addition, tablet waste associ-
ated with programmatic inefficiencies (e.g., tablets
not consumed before their expiration dates) was
not addressed in this study—these costs would
be greater for the more expensive MMS than for
IFA, ceteris paribus. Future work will address these
issues, too.
The study has several major strengths. First,
we develop and use the first model to explicitly
and transparently estimate the benefits and the
costs associated with shifting from IFA to MMS
for a disaggregated population, including varying
population characteristics (baseline rates of birth
outcomes) and prevalence of characteristics that
modify the effects of MMS compared with IFA.
Second, the model can compare benefits and costs,
and hence generate estimates of cost-effectiveness
for specific mortality and adverse birth outcomes,
and summary measures (e.g., DALYs). Third, the
key underlying assumptions regarding population
characteristics, coverage rates of IFA programs, and
tablet costs can be modified easily in the model to
assess the effects of changes in parameters on the
effects, costs, and cost-effectiveness of shifting from
mAdose–response relationship between number of tablets
consumed and expected health outcomes could be postu-
lated, but data are insufficient tomodel potential increases
in effects beyond 180 tablets or smaller but nonzero effects
among individuals who consumed some, but fewer than
180, tablets.
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IFA to MMS. Fourth, and related, the model can
easily be applied to different countries, or regions
within countries.
The results presented in this paper will be of
immediate interest to policymakers in Bangladesh
and Burkina Faso, and in countries with similar
characteristics, particularly with regard to the bur-
den of adverse birth outcomes. The results of this
simple application of themodel suggest that shifting
from IFA to MMS likely will be very cost-effective.
More complete and realistic scenarios will likely
reduce estimates of cost-effectiveness, but transi-
tion costs alone are not likely to reduce estimates
to levels below those that merit policy attention in
countries with reasonably well-performing IFApro-
grams. The samemay not be true for countries with
low antenatal care attendance or poor-performing
IFA programs. Adherence to consumption proto-
col (180 tablets per pregnancy), and the potential
for consumption of multiple micronutrient tablets
below or in excess of the 180-tablet protocolmay, on
the other hand, dramatically reduce expected bene-
fits of shifting from IFA toMMS, so policy and pro-
grammatic attention should focus on this key issue.
Policymakers in other countries should con-
sider adopting andmodifying the underlyingmodel
to better fit their realities (demographic charac-
teristics, micronutrient deficiencies, IFA program
performance, etc.) and use it to better inform
the policy discussions around the shift from IFA
to MMS. The results presented here will provide
insights into key country-specific characteristics
that are likely to lead to higher (or lower) expected
benefits, and to higher (or lower) expected costs.
Conclusions
Population-based models should be developed and
used to predict the mortality and birth outcome
benefits, and the costs, of shifting from IFA toMMS
during pregnancy. A model developed for the cases
of Bangladesh and Burkina Faso and used to explore
the single-year benefits and costs of a complete and
immediate shift from IFA toMMS suggests that this
policy would cost-effectively save lives and reduce
life-long disabilities. Further research is needed on
more realistic transition scenarios for shifting from
IFA to MMS, on more complete characterization of
delivery platform performance, and on more com-
plete modeling of adherence by pregnant women
to prescribed supplementation regimens. Stronger
economic cases can bemade for switching from IFA
toMMS as the threshold number of tablets required
to accrue benefits declines, and improvements in
program delivery and supplement adherence would
be expected to improve the cost-effectiveness of
replacing IFA with MMS.
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